Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and Lenvatinib in Mismatch Repair Proficient Recurrent Endometrial Cancer
NCT07594015Phase 2Recruiting
- Sponsor
- University of Miami
- Start
- Aug 2026
- Primary completion
- Aug 2031
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab, lenvatinib in endometrial cancer (EC), sponsored by University of Miami. Started Aug 2026; status: recruiting.
02
Drugs
pembrolizumablenvatinib
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT07594015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07594015.